Two Makers of Oral Mucositis Treatments Plan to Address Investors This Week
Two companies promoting their treatments for Oral Mucositis plan to make presentations this week before Wall Street investors.
The outreach is a reminder that medical advancements often require large amounts of capital, which in turn means that small pharmaceutical companies not only must master research and development, but marketing and fund-raising as well.
Beginning September 9 and running through September 11, investment bank Rodman & Renshaw will hold its Annual Global Investment Conference in New York. This year, the R&R event will include presentations from more than 500 companies that both present to and meet one-on-one with many of the institutional investors, venture capitalists and private equity managers who attend.
For small biotech and pharmaceuticals companies, the Rodman & Renshaw forum is one of the most important investor forums of the year. This year, according to R&R, as many as 3,500 attendees are expected. Dr. Alan Greenspan, former head of the Federal Reserve System, is a keynote speaker.
On Friday, Jeffrey B. Davis, president and CEO of Access Pharmaceuticals, is scheduled to provide a corporate overview and discuss the company's product opportunities. These include MuGard, an FDA-approved advancement in the treatment of oral mucositis which is currently rolling out in Europe and will be available in the United States in 2010.
"We think MuGard's commercial value is compelling, based on its use in the large, underserved oncology market," wrote Griffin Securities in a July 30th report. "[MuGard's] formulation is well liked by patients, as it has a pleasing flavour and may be swallowed without concern."
On Thursday, Friedhelm Blobel, president and CEO of SciClone Pharmaceuticals, will make a presentation at the R&R conference. Among the products in SciClone's pipeline is SCV-07, which the company says is "in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck."
A live link to both Access Pharmaceuticals and SciClone's sessions are available via links from their respective web sites.
The outreach is a reminder that medical advancements often require large amounts of capital, which in turn means that small pharmaceutical companies not only must master research and development, but marketing and fund-raising as well.
Beginning September 9 and running through September 11, investment bank Rodman & Renshaw will hold its Annual Global Investment Conference in New York. This year, the R&R event will include presentations from more than 500 companies that both present to and meet one-on-one with many of the institutional investors, venture capitalists and private equity managers who attend.
For small biotech and pharmaceuticals companies, the Rodman & Renshaw forum is one of the most important investor forums of the year. This year, according to R&R, as many as 3,500 attendees are expected. Dr. Alan Greenspan, former head of the Federal Reserve System, is a keynote speaker.
On Friday, Jeffrey B. Davis, president and CEO of Access Pharmaceuticals, is scheduled to provide a corporate overview and discuss the company's product opportunities. These include MuGard, an FDA-approved advancement in the treatment of oral mucositis which is currently rolling out in Europe and will be available in the United States in 2010.
"We think MuGard's commercial value is compelling, based on its use in the large, underserved oncology market," wrote Griffin Securities in a July 30th report. "[MuGard's] formulation is well liked by patients, as it has a pleasing flavour and may be swallowed without concern."
On Thursday, Friedhelm Blobel, president and CEO of SciClone Pharmaceuticals, will make a presentation at the R&R conference. Among the products in SciClone's pipeline is SCV-07, which the company says is "in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck."
A live link to both Access Pharmaceuticals and SciClone's sessions are available via links from their respective web sites.
Posted by Oral Mucosistis Newsroom at 9/8/2009 4:04 PM 
Categories: The Oral Mucositis Community
Tags: chemotherapy treatments investors radiation cancer oral mucositis Wall Street biotech prevention
Categories: The Oral Mucositis Community
Tags: chemotherapy treatments investors radiation cancer oral mucositis Wall Street biotech prevention
Comments